Top of this page
Skip navigation, go straight to the content

Investors UCB Stories

UCB Stories

  • 2012 gets off on the right foot

    Posted by

    Net sales of UCB’s three core medicines were up 50% in the first three months of 2012 compared with the same period last year. That’s one of take-home messages for the year so far. The other one is a significant pipeline performance.

    Read more

  • Introducing the UCB Annual Report 2.0

    Posted by

    For the first time, the UCB Annual Report is an "online" publication. More visual and more concise, we’ve made it easier to use and saved some trees in the process.

    Read more

  • 2011 was a good year for UCB

    Posted by

    Last year was another good one - paving the way for sustainable company growth

    Read more

  • Sharing the good news…

    Posted by

    Where did the Christmas holidays go? Somehow it’s almost February already but at least January brought a major piece of good news: we won an award!

    Read more

  • Q3 financial results show UCB is on track

    Posted by

    Read more

  • UCB 'on the road again'

    Posted by


    Read more

  • UCB delivers strong results

    Posted by


    Read more

  • UCB off to good start in 2011

    Posted by

    Financial figures published on April, 28 reveal UCB got off to a strong start with total revenue increasing by 13% to €893 million in the first quarter of the year.

    Read more

  • 2010 Annual Report

    Posted by

    Annual Report shows UCB’s biopharma aspirations on track

    The 2010 Annual Report is now available on the UCB website. Offering more than just financial results, this year’s report highlights and analyses UCB’s 2010 activities as it advanced its goals of becoming the patient-centric biopharmaceutical leader.

    Read more